Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Genetic Technologies (GNTLF)
OTHER OTC:GNTLF
RESEARCH TOOLSreports
Holding GNTLF?
Track your performance easily
GNTLF Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.00 - $6.18
Previous Close$0.5
Volume109.00
Average Volume (3M)109.00
Market Cap
$6.16M
Enterprise Value$6.05M
Total Cash (Recent Filing)AU$1.04M
Total Debt (Recent Filing)AU$875.19K
Price to Earnings (P/E)―
Beta15.50
Next Earnings
Feb 26, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding1
10 Day Avg. Volume0
30 Day Avg. Volume109
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)0.00
Price to Sales (P/S)1.63
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Genetic Technologies News
PremiumCompany Announcements
Genetic Technologies Enters Voluntary Administration
PremiumCompany Announcements
Genetic Technologies Extends Securities Offer Deadline
PremiumCompany Announcements
Genetic Technologies Extends Entitlement Offer Deadline
PremiumCompany Announcements
Genetic Technologies Extends Offer and Suspends Trading
PremiumCompany Announcements
Genetic Technologies Reduces Costs and Expands Global Reach
PremiumCompany Announcements
Genetic Technologies Extends Voluntary Suspension for Strategic Moves
PremiumCompany Announcements
Genetic Technologies Halts Trading Amid Strategic Assessment
PremiumCompany Announcements
Genetic Technologies Secures R&D Tax RefundRisk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
GNTLF FAQ
What was Genetic Technologies’s price range in the past 12 months?
Genetic Technologies lowest stock price was $0.00 and its highest was $6.18 in the past 12 months.
What is Genetic Technologies’s market cap?
Currently, no data Available
When is Genetic Technologies’s upcoming earnings report date?
Genetic Technologies’s upcoming earnings report date is Feb 26, 2025 which is in 95 days.
How were Genetic Technologies’s earnings last quarter?
Genetic Technologies released its earnings results on Aug 29, 2024. The company reported -$0.026 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.026.
Is Genetic Technologies overvalued?
According to Wall Street analysts Genetic Technologies’s price is currently Overvalued.
Does Genetic Technologies pay dividends?
Genetic Technologies does not currently pay dividends.
What is Genetic Technologies’s EPS estimate?
Genetic Technologies’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Genetic Technologies have?
Currently, no data Available
What happened to Genetic Technologies’s price movement after its last earnings report?
Genetic Technologies reported an EPS of -$0.026 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Genetic Technologies?
Currently, no hedge funds are holding shares in GNTLF
---
Genetic Technologies Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bearish
GNTLF Sentiment 100%
Sector Average 72%
Sector Average 72%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
―
20 days / 200 days
Momentum
-83.56%
12-Months-Change
Fundamentals
Return on Equity
-181.97%
Trailing 12-Months
Asset Growth
-58.22%
Trailing 12-Months
Company Description
Genetic Technologies
Genetic Technologies Ltd. engages in the provision of molecular risk assessment for cancer. It operates through the USA and Australia geographical segments. Its product, BREVAGenplus, is a clinically validated risk assessment test for non-hereditary breast cancer. The company was founded on January 5, 1987 and is headquartered in Fitzroy, Australia.
---
Technical Analysis
---